What is the clinical evidence from this study?

Study design: Other. Population: Hypertrophic cardiomyopathy (n=1). Intervention: Reprogramming via Sendai virus vectors. Primary outcome: Generation of a patient-specific induced pluripotent stem cell (iPSC) line.

September 23, 2025Stem Cell ResearchOpen Access

Establishment of an induced pluripotent stem cell line (HMUCPi001-A) from a hypertrophic cardiomyopathy patient carrying MYBPC3 c.3072C > A mutation

View Full Paper

Ask AI

Bookmark

Key result

Reprogramming peripheral blood mononuclear cells from an HCM patient with a MYBPC3 mutation successfully generated an iPSC line exhibiting normal morphology, karyotype, and pluripotency.

Why the study?

MYBPC3 is the most frequently mutated gene leading to HCM, an inherited cardiovascular disorder with elevated risk of sudden cardiac death.

Design

In vitro cell line establishment study

Authors

DLDongping Liu MYMing‐Yu Yang SFShasha Fan

Discussion

Member takes

Overview

iPSC model from MYBPC3-mutant HCM patient generated; leaves open utility for mechanistic studies or drug testing.

Structured PICO

Population

Peripheral blood mononuclear cells from one patient with hypertrophic cardiomyopathy and a heterozygous MYBPC3 missense mutation were used to generate an iPSC line.

Intervention

Reprogramming via Sendai virus vectors to generate a patient-specific induced pluripotent stem cell (iPSC) line (HMUCPi001-A)

Outcome

Establishment of an iPSC line exhibiting normal morphology, karyotype, and pluripotency hallmarks

The establishment of this patient-specific iPSC line provides a valuable in vitro model for studying the disease mechanisms of HCM associated with the MYBPC3 c.3072C > A mutation.

Cite This Study

Liu et al. (2025) studied Hypertrophic cardiomyopathy (n=1). Reprogramming via Sendai virus vectors was evaluated on Generation of a patient-specific induced pluripotent stem cell (iPSC) line. Reprogramming peripheral blood mononuclear cells from an HCM patient with a MYBPC3 mutation successfully generated an iPSC line exhibiting normal morphology, karyotype, and pluripotency.

synapsesocial.com/papers/6a88332efc0635f4eccf0b89 https://doi.org/10.1016/j.scr.2025.103841

View Full Paper

Ask AI

Bookmark

September 23, 2025Stem Cell ResearchOpen Access

Establishment of an induced pluripotent stem cell line (HMUCPi001-A) from a hypertrophic cardiomyopathy patient carrying MYBPC3 c.3072C > A mutation

View Full Paper

Ask AI

Bookmark

Key result

Reprogramming peripheral blood mononuclear cells from an HCM patient with a MYBPC3 mutation successfully generated an iPSC line exhibiting normal morphology, karyotype, and pluripotency.

Why the study?

MYBPC3 is the most frequently mutated gene leading to HCM, an inherited cardiovascular disorder with elevated risk of sudden cardiac death.

Design

In vitro cell line establishment study

Authors

DLDongping Liu MYMing‐Yu Yang SFShasha Fan

Discussion

Member takes

Overview

iPSC model from MYBPC3-mutant HCM patient generated; leaves open utility for mechanistic studies or drug testing.

Structured PICO

Population

Peripheral blood mononuclear cells from one patient with hypertrophic cardiomyopathy and a heterozygous MYBPC3 missense mutation were used to generate an iPSC line.

Intervention

Reprogramming via Sendai virus vectors to generate a patient-specific induced pluripotent stem cell (iPSC) line (HMUCPi001-A)

Outcome

Establishment of an iPSC line exhibiting normal morphology, karyotype, and pluripotency hallmarks

The establishment of this patient-specific iPSC line provides a valuable in vitro model for studying the disease mechanisms of HCM associated with the MYBPC3 c.3072C > A mutation.

Cite This Study

synapsesocial.com/papers/6a88332efc0635f4eccf0b89 https://doi.org/10.1016/j.scr.2025.103841

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark